ArticleNature2026
Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Finishing the fight against HIV.Nature microbiology · 2026Article
- Apex-guided HIV vaccination: liposome-displayed Env trimers elicit PG9-like cross-neutralizing antibodies.Signal transduction and targeted therapy · 2026Article
- Article
- Article
- Article
- HIV-1 BG505 SOSIP immunization induced B cell expansion targeting the 465-glycan hole, with neutralizing antibodies exhibiting distinct binding modes and mechanisms of virus inhibition.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Javier Guenaga *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Monika Ádori *Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0009-0002-7679-0873
Shridhar Bale *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Swastik Phulera *Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1272-7712
Ioannis ZygourasDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-3247-9530
Fabian-Alexander SchleichDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0009-0006-6824-4310
Xaquin Castro DopicoDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-9005-6774
Sashank AgrawalDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Miyo OtaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Richard WilsonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jocelyn CluffDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Tamar DzvelaiaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Marco MandolesiDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Wen-Hsin LeeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-9445-6671
Agnes A WalshDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Mariane B MeloDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0409-2454
Laurent VerkoczyApplied Biomedical Science Institute, San Diego, CA, USA.
Darrell J IrvineDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8637-1405
Martin CorcoranDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6469-2419
Diane CarnathanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6602-2470
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7153-3769
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9695-8138
Gunilla B Karlsson Hedestam *Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. gunilla.karlsson.hedestam@ki.se.ORCID http://orcid.org/0000-0001-7255-9047
Richard T Wyatt *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. wyatt@scripps.edu.ORCID http://orcid.org/0000-0001-7085-1351
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MProject 2_NillaP01AI157299 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2021 to 2025
$17.3MNon-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI KARLSSON HEDESTAM, GUNILLA · 2014 to 2018
$14.6MPushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogensP01AI124337 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI RASMUSSEN, BETH · 2016 to 2020
$12.2MNIAID NIH HHS P01 AI104722NIAID NIH HHS P01 AI124337NIAID NIH HHS P01 AI157299NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011132
Abstract
As a chronically replicating virus, HIV has evolved extreme sequence variability and effective shielding of functionally constrained spike protein determinants by host-derived glycans
Indexed as
AIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesAnimalsAntibodies, MonoclonalCross ReactionsCryoelectron MicroscopyFemaleHIV InfectionsHumansLiposomesMacaca mulattaMaleModels, MolecularAIDS VaccinesAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesLiposomes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.